Semaglutide and kidney disease: what the FLOW trial shows

TL;DR

The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease and followed them for a median of 3.4 years on subcutaneous semaglutide 1 mg weekly. Semaglutide reduced major kidney outcomes by 24%, cardiovascular death, heart attack, and stroke by 18%, and all-cause mortality by 20%. Benefits were consistent across CKD severity levels. Researchers are calling semaglutide a potential fourth therapeutic pillar for diabetic kidney disease.

Diabetic kidney disease is the leading cause of kidney failure in high-income countries. Most people prescribed semaglutide for weight loss don't have CKD - but a meaningful number do, and many more are at risk. The FLOW data changes how clinicians should think about who benefits most from these medications.

What the FLOW trial was designed to test

FLOW (Flow Investigating Renal Outcomes With Semaglutide) was a randomised, double-blind, placebo-controlled trial specifically designed to assess kidney outcomes - not weight loss or glucose control as the primary goal. This distinction matters. Earlier cardiovascular trials like SELECT and LEADER had spotted renal signals as secondary findings. FLOW was built from the ground up to answer the kidney question definitively.

The 3,533 participants all had type 2 diabetes and chronic kidney disease confirmed at baseline. Nearly 70% were in the very high KDIGO risk category (the most severe CKD risk tier). Participants received subcutaneous semaglutide 1 mg weekly or placebo on top of their existing standard-of-care treatments, which for many included ACE inhibitors, SGLT2 inhibitors, or both.

Median follow-up was 3.4 years - long enough to capture hard kidney outcomes like dialysis, kidney transplant, and sustained decline in kidney function.

The headline results

The primary composite kidney outcome - defined as kidney failure, a sustained 50% or greater decline in kidney function (eGFR), or kidney or cardiovascular death - was reduced by 24% with semaglutide compared to placebo.

The cardiovascular and mortality data was equally strong:

Composite of cardiovascular death, heart attack, and stroke: 18% reduction (hazard ratio 0.82, 95% CI 0.68-0.98, P=0.03)
All-cause mortality: 20% reduction (hazard ratio 0.80, 95% CI 0.67-0.95, P=0.01)

In practical terms: the number needed to treat to prevent one cardiovascular event was 45, and to prevent one death was 39. Over 3.4 years of treatment, those are meaningful numbers for a population at very high baseline risk.

Did CKD severity change the results?

One of the most clinically important findings was the consistency of benefit across CKD severity categories. Whether patients were in the low-to-moderate, high, or very high KDIGO risk tier, the cardiovascular and mortality benefits held. This matters because clinicians have historically been cautious about initiating new medications in patients with impaired kidney function - the FLOW data challenges that caution for semaglutide specifically.

There was one notable exception: for all-cause mortality, the benefit appeared concentrated in patients with a urine albumin-to-creatinine ratio (UACR) of 300 mg/g or more. For patients with UACR below that threshold, the mortality benefit was not statistically significant. Albuminuria - protein in the urine - is a marker of kidney damage severity, and this finding suggests the mortality benefit may be particularly strong in patients with more active kidney injury.

Why does semaglutide protect the kidneys?

The mechanisms are not fully resolved, but several pathways are plausible and under active investigation.

Reduced intraglomerular pressure

GLP-1 receptor activation appears to dilate the arteriole bringing blood into the kidney's filtering units (glomeruli), which reduces the pressure inside them. High intraglomerular pressure is a primary driver of diabetic kidney damage - the same reason ACE inhibitors and SGLT2 inhibitors protect the kidneys. Semaglutide may add an independent pressure-lowering effect on top of these.

Metabolic improvements

Weight loss, improved insulin sensitivity, and lower blood glucose all reduce the metabolic stress on kidney tissue. In diabetic CKD, hyperglycaemia and insulin resistance directly damage kidney tubules and glomeruli over time. Semaglutide addresses these root drivers comprehensively.

Anti-inflammatory and anti-fibrotic effects

Chronic inflammation accelerates kidney fibrosis. Early research suggests GLP-1 receptor activation may reduce oxidative stress and inflammatory signalling in kidney tissue, though most of this evidence is preclinical and the human mechanisms need further characterisation.

What this means for the treatment landscape

Before FLOW, the established protective treatments for diabetic kidney disease were three: ACE inhibitors or ARBs (which lower intraglomerular pressure), SGLT2 inhibitors (which reduce glucose reabsorption and also lower intraglomerular pressure), and finerenone (a mineralocorticoid receptor antagonist that reduces inflammation and fibrosis). FLOW makes a strong case that semaglutide is now a fourth therapeutic pillar - with a different mechanism profile from the existing three.

The ADA Meeting News coverage of FLOW characterised it as "a paradigm shift for diabetic kidney disease treatment." That framing reflects the scale of the mortality benefit - 20% reduction in all-cause mortality over 3.4 years is a substantial effect for a population where treatment options have been limited.

Nutrition and kidney disease on GLP-1 medications

For people with CKD using semaglutide, nutritional monitoring becomes doubly important. Kidney disease itself affects nutrient metabolism - potassium, phosphorus, and vitamin D management are standard concerns in CKD. GLP-1 medications add a separate layer of depletion risk for vitamin D, vitamin B12, iron, and protein.

Protein is particularly nuanced: GLP-1 patients are typically advised to maintain high protein intake to preserve muscle, but CKD patients are often told to restrict protein to reduce kidney workload. These two recommendations point in opposite directions. Discussing the right protein target with your nephrologist is essential - the correct answer depends on CKD stage and whether you're on dialysis.

At GLP-1 Shield, we design our formulations with the specific nutrient gaps of GLP-1 users in mind. For users who also have kidney disease, talking to your physician before adding any supplement is especially important, given the complex nutrient regulation that CKD requires.

Are you eligible for semaglutide if you have CKD?

Historically, kidney impairment raised prescribing concerns with older diabetes medications. Semaglutide does not require dose adjustment for any level of kidney function - including patients on dialysis - because it is not renally cleared. The FLOW trial specifically enrolled patients with impaired kidney function and found the drug safe and effective in this population.

If you have type 2 diabetes and CKD and are not yet on a GLP-1 medication, the FLOW data is a strong evidence base to discuss with your nephrologist or endocrinologist. If you're already on semaglutide for weight loss and also have CKD, the FLOW trial suggests you may be getting kidney protection as a meaningful additional benefit.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

Frequently asked questions

Does semaglutide protect the kidneys?: Yes, based on the FLOW trial. Semaglutide 1 mg weekly reduced major kidney outcomes by 24%, cardiovascular events by 18%, and all-cause mortality by 20% in 3,533 people with type 2 diabetes and chronic kidney disease over 3.4 years. Benefits were consistent across different levels of CKD severity.
Can you take Ozempic if you have kidney disease?: Semaglutide (Ozempic, Wegovy) does not require dose adjustment for kidney impairment at any stage, including dialysis, because it is not cleared by the kidneys. The FLOW trial enrolled patients with significant CKD and found semaglutide safe and effective. However, any medication decision in CKD should be made with your nephrologist or prescribing physician.
What was the FLOW trial?: FLOW was a Phase 3 randomised controlled trial specifically designed to assess kidney outcomes with semaglutide in people with type 2 diabetes and chronic kidney disease. It enrolled 3,533 participants and followed them for a median of 3.4 years on subcutaneous semaglutide 1 mg weekly versus placebo.
Should I take protein supplements if I have CKD and am on a GLP-1 medication?: This depends on your CKD stage. GLP-1 guidelines generally recommend high protein intake to preserve muscle during weight loss, while CKD guidelines often recommend protein restriction to reduce kidney workload. These recommendations conflict. Discuss your specific protein target with your nephrologist before making changes - the right answer varies significantly by CKD stage and whether you are on dialysis.